Hold at $61.08 with $58.50 stop: defend floor, collect 3.46% yield, await momentum confirmation before scaling
This is a discipline test, not an alpha test. The structural floor at $58.82 is defended by 42+ sessions of support and rising $0.50-$1.00/month, the 9.46% dividend yield provides real carry, and the prior 9/21 trim generating +1.5% alpha against SPY binds against further reduction. However, broken short-term momentum (10 EMA below 50 SMA, MACD histogram at -0.20) and incomplete margin recovery (8.0% vs 17-22% historical range) prevent aggressive additions. The Neutral analyst's framework — Hold with $58.50 stop, scaled adds only on confirmed basing evidence with strict size caps, mandatory alpha-loss trim trigger per 9/16/9/17 lessons — is the correct synthesis that addresses prior failure modes. Maintain ~75% target weight, defend $58.50 structural stop, collect 3.46% dividend as carry, and let technicals resolve before committing incremental capital.
| Position | Action |
|---|---|
| Current position ~75% of target weight (post 9/21 trim) | Maintain current exposure; do NOT trim further absent structural break below $58.50 |
| Scaled entry on basing evidence — Tranche 1 (~1/3 of available capital) | Higher low above $60.50 with MACD histogram compressing toward zero, OR two consecutive closes above 10 EMA with declining volume on bounce |
| Scaled entry on higher-quality confirmation — Tranche 2 (~2/3 of available capital) | 50 SMA reclaim at $62.03 with positive MACD crossover, OR clean close above $62.00 on volume ≥10M |
| MDLZ underperforms SPY by -2% over 10 sessions while structural floor holds intact | Trim ~15% of remaining position into strength (mandatory alpha-loss trim trigger per 9/16/9/17 lessons) |
| Confirmed close below $58.50 on volume ≥10M (structural break) | Trim remaining position aggressively; full exit of residual position |
MDLZ is a mega-cap consumer-defensive compounder trading at PEG 0.89 with a confirmed Q1 2026 margin inflection, sitting in a textbook pullback within an intact long-term uptrend—the bear is using short-term tape noise to argue against the dominant fundamental reality.
| Indicator | Value | Signal |
|---|---|---|
| 200 SMA | 58.82 | bullish |
| 50 SMA | 62.03 | neutral |
| 10 EMA | 61.54 | bearish |
| MACD Line | -0.31 | bearish |
| MACD Signal Line | -0.11 | bearish |
| MACD Histogram | -0.20 | bearish |
| RSI (14) | 43.93 | neutral |
| Bollinger Middle Band (20 SMA) | 61.98 | neutral |
| Bollinger Upper Band | 63.43 | neutral |
| Bollinger Lower Band | 60.53 | neutral |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Close >$62.03 (50 SMA) on volume ≥10M with rising MACD histogram
Then: Reclaims short-term momentum and re-establishes bullish moving-average stack; re-engage with scaled adds
↩ rebuts: “Bear's reliance on 10 EMA/50 SMA cross and negative MACD as trend-breaking signals”
EV: +5.9% (base case retest of August high $64.70); +8%+ (bullish case $66+ retest) · concedes: Zacks' central question on H2 gum/candy durability is a measured hedge, not a thesis-killer—the bull acknowledges momentum needs H2 confirmation; Technical report's HOLD is technically defensible for someone wanting a perfect setup; Bear's sugar price concern is acknowledged (though cocoa is 3-4x more important to COGS)
MDLZ is a mid-cycle margin reset being misinterpreted as a buying opportunity, where a single +39% Q1 NI print off a depressed base is being used to justify ignoring deteriorating short-term technicals, debt-funded capital returns that just paused, inventory glut, and a catalyst pipeline that's mostly 12+ months away from impacting the P&L.
EV: -3.7% downside to 200 SMA at $58.82 (base case); -16-25% downside ($10-15) if 200 SMA breaks (bear case) · concedes: MDLZ is a high-quality business with iconic brands and a long-term defensible moat; Cocoa normalization could provide margin relief if sustained; One positive Q1 print is possible even in an unconfirmed recovery; Oreo is an iconic brand with eventual relaunch upside; Dividend at 3.46% provides income while waiting for clarity
→ vs conservative: Conservative wait-for-confirmation triggers (50 SMA reclaim at 62.03 with rising MACD, or 200 SMA test at 58.82 with RSI below 35) require 4-6% more downside — this is paralysis, not risk management
→ vs conservative: 50-SMA and 200-SMA-based stops at 58.50 are too tight for a defensive compounder; give the trade room to breathe to 55-57 zone
→ vs conservative: HOLD rating leaves meat on the table on a value-plus-catalyst-plus-income trade with 0.4 beta and 3.46% yield
| ATR (14) |
| 1.23 |
| neutral |
| Price Close (9/22) | 61.08 | neutral |
| 52-Week High | 64.70 | neutral |
| 52-Week Low | 36.54 (RSI) | neutral |
Support: 60.53 · 58.82 | Resistance: 62.03 · 63.43
MDLZ exhibits a mixed technical picture with a structurally intact long-term uptrend (price above rising 200 SMA at $58.82) conflicting with deteriorating short-term momentum (negative MACD, bearish EMA crossover, price below all short-term moving averages). The 200 SMA at $58.82 represents the "line in the sand" for the long-term thesis, while the 50 SMA at $62.03 is the key level to reclaim for bullish continuation. Bollinger Bands are contracting (squeeze setup), ATR has compressed to 1.23, and RSI bounced from 36.54 to 43.93, suggesting the pullback may be basing rather than reversing. Volume spike on 9/18 (17.7M shares) on a down-day flagged institutional distribution, but the 9/22 rebound on declining volume is mildly constructive.
Market Cap
$77.96B
Revenue 2021
$31.50B
Revenue 2022
$31.50B
Revenue 2023
$36.02B
Revenue 2024
$36.44B
Revenue 2025
$38.54B
Revenue TTM
$39.67B
Gross Profit 2021
$11.31B
Gross Profit 2022
$11.31B
Gross Profit 2023
$13.76B
Gross Profit 2024
$14.26B
Gross Profit 2025
$10.94B
Gross Profit TTM
$12.36B
Operating Income 2024
$6.67B
Operating Income 2025
$3.62B
Operating Income TTM
$8.72B
Net Income 2024
$4.61B
Net Income 2025
$2.45B
Net Income TTM
$3.52B
Diluted EPS 2021
$1.96
Diluted EPS 2022
$1.96
Diluted EPS 2023
$3.62
Diluted EPS 2024
$3.42
Diluted EPS 2025
$1.89
Diluted EPS TTM
$2.73
Operating Margin TTM
22.0%
Net Margin TTM
8.86%
Total Assets 2022
$71.16B
Total Assets 2023
$71.39B
Total Assets 2024
$68.50B
Total Assets 2025
$71.49B
Total Debt 2025
$21.80B
Net Debt 2025
$19.08B
Debt/Equity
82.6%
Stockholders' Equity 2024
$26.93B
Stockholders' Equity 2025
$25.84B
Goodwill + Intangibles 2025
$43.96B
Inventory 2024
$3.83B
Inventory 2025
$4.42B
Operating CF 2022
$3.91B
Operating CF 2023
$4.71B
Operating CF 2024
$4.91B
Operating CF 2025
$4.51B
Free Cash Flow 2022
$3.00B
Free Cash Flow 2023
$3.60B
Free Cash Flow 2024
$3.52B
Free Cash Flow 2025
$3.24B
Free Cash Flow TTM
$2.25B
Capex 2022
$0.91B
Capex 2023
$1.11B
Capex 2024
$1.39B
Capex 2025
$1.28B
Dividends Paid 2022
$1.99B
Dividends Paid 2023
$2.16B
Dividends Paid 2024
$2.35B
Dividends Paid 2025
$2.49B
Buybacks 2022
$2.02B
Buybacks 2023
$1.55B
Buybacks 2024
$2.33B
Buybacks 2025
$2.39B
Total Shareholder Returns 2022
$4.00B
Total Shareholder Returns 2023
$3.71B
Total Shareholder Returns 2024
$4.68B
Total Shareholder Returns 2025
$4.87B
P/E TTM
22.37
Forward P/E
18.18
PEG Ratio
0.89
P/B
2.94
Dividend Yield
3.46%
Beta
0.40
52-Week Range
$51.20–$66.65
200-Day MA
$59.37
Q1 2026 Revenue
$10.08B
Q1 2026 Net Income
$560M
Current Ratio
0.60
Receivables
$4.86B
Payables
$10.14B
Treasury Stock
$31.53B
Retained Earnings
$36.41B
Strengths
Concerns
MDLZ delivered strong revenue growth of +5.8% to $38.54B in 2025, but suffered a severe margin reset with gross profit plummeting ~1,070 bps to 28.4% as cocoa and dairy input costs surged, driving operating income down 45.6% to $3.62B and net income down 46.8% to $2.45B; Q1 2026 shows early recovery with revenue +8.2% YoY and net income +39%. The balance sheet reflects elevated leverage (net debt $19.08B, 3.1x Net Debt/EBITDA) partially funding massive shareholder returns of $4.87B in 2025 that exceeded operating cash flow, while valuation metrics (PEG 0.89, forward P/E 18.18, 3.46% yield) suggest reasonable to attractive levels assuming the margin compression is transitory and recovery continues through 2026.
Macro: Higher-for-longer rates: Polymarket pricing 96% no Fed cuts in 2026 (up +2.8pp WoW, $8.5M volume) with first hike since 2023; US recession odds at 8% YE26 (down -2.5 to -6.5pp WoW across regions). Supports consumer-defensive cash flows; headwind for rate-sensitive discretionary.